Celcuity (CELC) Non-Current Assets (2016 - 2026)
Celcuity's (CELC) quarterly Non-Current Assets came in at $899000.0 in Q4 2025, up 62.86% YoY from $552000.0 in Q4 2024, and up 77.32% on a QoQ basis from $507000.0 in Q3 2025.
Powered by 
Analysis
Celcuity (CELC) Non-Current Assets (2016 - 2026) Analysis & Trends
Celcuity (CELC) has 10 years of Non-Current Assets data on file, last reported at $899000.0 in Q4 2025.
- Quarterly Non-Current Assets rose 62.86% year-over-year to $899000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.4 million (changed 0.08% YoY) and the FY2025 annual result came in at $899000.0, up 62.86% from the prior year.
- Non-Current Assets rose to $899000.0 in Q4 2025, from $507000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $899000.0 in Q4 2025 to a low of $387356.0 in Q2 2022.
- A 5-year average of $601580.8 and a median of $598035.5 in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets slumped 32.56% — and 2023, when it surged 83.51%.
- Tracing CELC's Non-Current Assets over 5 years: stood at $554345.0 in 2021, then declined by 8.62% to $506560.0 in 2022, then rose by 24.13% to $628801.0 in 2023, then decreased by 12.21% to $552000.0 in 2024, then jumped by 62.86% to $899000.0 in 2025.
- The last three Non-Current Assets figures came in at $899000.0 (Q4 2025), $507000.0 (Q3 2025), and $488000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.15 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 294.93 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 18.06 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Celcuity | 5.25 Bn | 5.25 Bn | - | 52.38 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 52.38 Mn |
| Dec 31, 2025 | 899,000.00 |
| Sep 30, 2025 | 507,000.00 |
| Jun 30, 2025 | 488,000.00 |
| Mar 31, 2025 | 530,000.00 |
| Dec 31, 2024 | 552,000.00 |
| Sep 30, 2024 | 598,531.00 |
| Jun 30, 2024 | 613,623.00 |
| Mar 31, 2024 | 657,935.00 |
| Dec 31, 2023 | 628,801.00 |
| Sep 30, 2023 | 672,746.00 |
| Jun 30, 2023 | 710,851.00 |
| Mar 31, 2023 | 775,276.00 |
| Dec 31, 2022 | 506,560.00 |
| Sep 30, 2022 | 597,540.00 |
| Jun 30, 2022 | 387,356.00 |
| Mar 31, 2022 | 486,001.00 |
| Dec 31, 2021 | 554,345.00 |
| Sep 30, 2021 | 655,119.00 |
| Jun 30, 2021 | 557,846.00 |